Evidence map›Paper›PMID 40427220›Full record

ReviewCancers2025

Positron Emission Tomography Radiotracers for Identification of Site of Recurrence in Prostate Cancer After Primary Treatment Failure.

Ryan Bitar, Pablo Zurita, Lucia Martiniova, Amado J Zurita, Gregory C Ravizzini

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ryan BitarDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT 06510, USA.ORCID 0000-0002-1311-2234
Pablo ZuritaDepartment of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA.ORCID 0009-0005-8398-3093
Lucia MartiniovaDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Amado J ZuritaGenitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-3805-7307
Gregory C RavizziniDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite substantial improvement in the definitive management of primary prostate cancer, a significant number of patients experience biochemical recurrence-a clinical state in which serum prostate-specific antigen (PSA) levels rise prior to the development of physical signs or symptoms. The early detection and localization of biochemical recurrence may confer eligibility for salvage therapy; therefore, imaging techniques that provide accurate disease visualization are imperative. In this review, we discuss various imaging methods for localizing disease in the context of biochemical recurrence in prostate cancer. Particularly, we describe available or investigational positron emission tomography (PET) radiotracers, such as

Indexed as

biochemical recurrencePETprostate cancerPSMAPSMA-radioligandsradiotracer

Identifiers

PMID40427220
PMCPMC12109795

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.